立体定向体部放疗治疗多发转移患者的安全性评估:NRG-BR001 I期试验结果
NRG-BR001是一项I期试验,评估立体定向体部放疗(SBRT)用于3-4个转移灶或2个紧邻转移灶患者的安全性。共35例可评估患者,未观察到方案定义的剂量限制性毒性(DLT)。结论认为SBRT对这类患者是安全的,无治疗相关死亡,但晚期3级不良事件提示需长期随访。
要点
- SBRT治疗3-4个转移灶或2个紧邻转移灶未出现方案定义的DLT。
- 7例患者发生8次可能与方案治疗相关的3级不良事件,发生于SBRT开始后约125-556天。
- 无治疗相关死亡,但晚期毒性提示寡转移长期生存者需延长随访。
核心结论
- I期试验表明SBRT对3-4个转移灶或2个紧邻转移灶患者是安全的,无治疗相关死亡。
研究设计与样本
- I期试验,2014年8月4日开放,2018年3月20日停止入组,纳入乳腺、前列腺或非小细胞肺癌患者。
- 共入组42例,39例符合条件,35例可评估DLT(平均年龄63.1岁,20例男性,30例白人)。
- 转移部位包括骨、脊柱/椎旁、周围肺、中央肺、腹盆腔、纵隔/颈部淋巴结和肝脏,每个解剖部位最多入组6例。
主要发现
- 12例(34.3%)乳腺癌,10例(28.6%)非小细胞肺癌,13例(37.1%)前列腺癌;每例患者中位治疗转移灶数为3个。
- 未观察到方案定义的DLT。
- 7例患者发生8次可能与方案治疗相关的3级不良事件,发生于SBRT开始后约125至556天。
- 中位生存期未达到。
关键数值与推荐
- 起始剂量:中央肺和纵隔/颈部淋巴结为50 Gy/5次,周围肺、腹盆腔和肝脏为45 Gy/3次,骨和脊柱/椎旁为30 Gy/3次。
- DLT定义为SBRT治疗后180天内发生的与治疗相关的特定3-5级不良事件(根据CTCAE v4.0)。
- 若每个部位6例患者中DLT不超过1例,则该剂量水平被认为安全;否则降级。
临床怎么用
- 支持SBRT用于3-4个转移灶或2个紧邻转移灶患者的治疗。
- 对长期生存的寡转移患者需延长随访以监测晚期不良事件。
- 该结果已支持开展多项正在进行的随机II/III期试验(NRG-BR002、NRG-LU002)。
局限性
- I期试验样本量小,可评估患者仅35例。
- 随访时间可能不足以全面评估晚期毒性。
- 入组患者仅限乳腺、前列腺和非小细胞肺癌。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Stereotactic body radiotherapy (SBRT) for oligometastases is hypothesized to improve survival and is increasingly used. Little evidence supports its safe use to treat patients with multiple metastases. OBJECTIVE: To establish safety of SBRT dose schedules in patients with 3 to 4 metastases or 2 metastases in close proximity to each other. DESIGN, SETTING, AND PARTICIPANTS: This phase 1 trial opened on August 4, 2014, and closed to accrual on March 20, 2018. Metastases to 7 anatomic locations were included: bone/osseous (BO), spinal/paraspinal (SP), peripheral lung (PL), central lung (CL), abdominal-pelvic (AP), mediastinal/cervical lymph node (MC), and liver (L). Six patients could be enrolled per anatomic site. The setting was a consortium of North American academic and community practice cancer centers participating in NRG Oncology trials. Patients with breast, prostate, or non-small cell lung cancer with 3 to 4 metastases or 2 metastases in close proximity (≤5 cm) amenable to SBRT were eligible for this phase 1 study. Statistical analyses were performed from December 31, 2017, to September 19, 2019. INTERVENTIONS: The starting dose was 50 Gy in 5 fractions (CL, MC), 45 Gy in 3 fractions (PL, AP, L), and 30 Gy in 3 fractions (BO, SP). MAIN OUTCOMES AND MEASURES: The primary end point was dose-limiting toxicity (DLT) defined by the Common Terminology Criteria for Adverse Events, version 4.0, as specific adverse events (AEs) of grades 3 to 5 (definite or probable per the protocol DLT definition) related to SBRT within 180 days of treatment. Dose levels were considered safe if DLTs were observed in no more than 1 of 6 patients per location; otherwise, the dose at that location would be de-escalated. RESULTS: A total of 42 patients enrolled, 39 were eligible, and 35 (mean [SD] age, 63.1 [14.2] years; 20 men [57.1%]; 30 White patients [85.7%]) were evaluable for DLT. Twelve patients (34.3%) had breast cancer, 10 (28.6%) had non-small cell lung cancer, and 13 (37.1%) had prostate cancer; there was a median of 3 metastases treated per patient. Median survival was not reached. No protocol-defined DLTs were observed. When examining all AEs, 8 instances of grade 3 AEs, most likely related to protocol therapy, occurred approximately 125 to 556 days from SBRT initiation in 7 patients. CONCLUSIONS AND RELEVANCE: This phase 1 trial demonstrated the safety of SBRT for patients with 3 to 4 metastases or 2 metastases in close proximity. There were no treatment-related deaths. Late grade 3 AEs demonstrate the need for extended follow-up in long-surviving patients with oligometastatic disease. Treatment with SBRT for multiple metastases has been expanded into multiple ongoing randomized phase 2/3 National Cancer Institute-sponsored trials (NRG-BR002, NRG-LU002). TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT02206334.
引用
- Chmura S, Winter KA, Robinson C, et al. Evaluation of Safety of Stereotactic Body Radiotherapy for the Treatment of Patients With Multiple Metastases: Findings From the NRG-BR001 Phase 1 Trial. JAMA Oncol. 2021. PMID: 33885704. doi:10.1001/jamaoncol.2021.0687
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。